Shots :
- Following the approval from the Drug Controller General of India (DCGI), Glenmark has introduced the first biosimilar of Liraglutide under the brand name Lirafit (1.2mg, per day) for managing type 2 diabetes mellitus in India
- Lirafit gained approval based on a 24wks. study in type 2 diabetes mellitus Indian adult patients which showed its effectiveness, safety, and good tolerance. Its efficacy and safety profile were found to be non-inferior to the reference liraglutide
- The reference drug, Liraglutide, is a GLP‐1 receptor agonist that enhances glucose-dependent insulin secretion and reduces inappropriate glucagon secretion in adult patients. It is approved in both the US and the EU
Ref: PR Newswire | Image: Glenmark | Press Release
Related News:-Alvotech Reports Topline Results from the Study of AVT06 (Biosimilar, Eylea) for Eye Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
